
Imugene Limitedrevenue & market cap
Sydney, New South Wales, AustraliaFounded 2012
Public companyImugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients.
Imugene Limited revenue
Imugene Limited's annual revenue was $1.5M in June 2026 (Stock Analysis; converted from Australian dollars).
$0
$1M
$2M
$3M
$0
–
$3.1M
$1.5M
20122013–2420252026
All 2 revenue readings, with sources
| As of | Revenue | Source |
|---|---|---|
| Jun 2025 | $3.1M | Stock Analysisconverted from Australian dollars |
| Jun 2026 | $1.5M | Stock Analysisconverted from Australian dollars |
Imugene Limited market cap
Imugene Limited is a public company. Its market capitalisation was $16.1M in September 2026.
Imugene Limited FAQ
Categories
How this page is sourced
2 from public sources. Founder figures link to the second they were said; public figures name their source; estimates are marked EST and say whose they are. Not financial advice.
Updated Sep 28, 2026Data disclaimerReport a correctionClaim this profileRun Imugene Limited? Join the podcast